Propiedad y actividad de insiders de Protalix BioTherapeutics, Inc. (PLX): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $2.68 |
| Capitalización | $216M |
| Bolsa | AMEX |
| País | US |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $63.3M | $51.2M | $37.8M | $17.8M | $18.3M | $39.0M | $17.1M | $23.6M | $19.8M | $14.7M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | $20.3M | 0 | $5.1M | $20.9M | $15.1M | $15.6M |
| Cuentas por Cobrar | $693000 | $1.7M | $4.7M | $4.7M | $2.0M | $3.4M | $4.6M | $5.3M | $2.9M | $8.8M |
| Inventario | $5.2M | $7.8M | $8.6M | $8.2M | $13.1M | $18.0M | $16.8M | $19.0M | $21.2M | $25.7M |
| Activos Corrientes | $71.9M | $62.7M | $53.0M | $32.5M | $55.7M | $61.7M | $44.9M | $69.9M | $60.1M | $66.7M |
| Inmovilizado Material | $8.7M | $7.7M | $6.4M | $10.9M | $10.4M | $9.9M | $9.6M | $10.9M | $10.0M | $12.6M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $82.2M | $72.2M | $61.1M | $45.4M | $67.9M | $73.7M | $55.8M | $84.4M | $73.4M | $82.3M |
| Cuentas por Pagar | $4.0M | $7.5M | $5.2M | $6.5M | $7.2M | $7.0M | $5.9M | $4.3M | $4.5M | $5.3M |
| Deuda a Corto | $53.9M | $5.9M | 0 | $4.3M | $58.5M | 0 | 0 | $21.7M | 0 | 0 |
| Pasivos Corrientes | $66.2M | $22.8M | $25.4M | $40.2M | $86.5M | $33.2M | $32.4M | $45.5M | $25.6M | $26.5M |
| Deuda a Largo | $23.6M | $46.3M | $48.0M | $51.0M | 0 | $27.9M | $28.2M | 0 | 0 | 0 |
| Pasivos Totales | $92.2M | $103.5M | $114.0M | $115.7M | $95.0M | $79.7M | $66.4M | $50.9M | $30.2M | $34.1M |
| Reservas | -$212.7M | -$297.9M | -$322.6M | -$340.8M | -$347.4M | -$374.9M | -$389.9M | -$381.5M | -$378.4M | -$385.0M |
| Patrimonio Neto | -$10.0M | -$31.3M | -$52.9M | -$70.3M | -$27.0M | -$6.0M | -$10.6M | $33.6M | $43.2M | $48.2M |
| Deuda Total | $77.5M | $52.2M | $48.0M | $60.9M | $64.4M | $33.5M | $33.5M | $27.7M | $5.5M | $8.3M |
| Deuda Neta | $14.2M | $1.0M | $10.2M | $43.1M | $25.9M | -$5.5M | $11.3M | -$16.9M | -$29.3M | -$22.0M |
| Capital Circulante | $5.7M | $39.9M | $27.6M | -$7.7M | -$30.8M | $28.5M | $12.5M | $24.4M | $34.5M | $40.2M |
Salud financiera
| Deuda / Patrimonio | 0.13 |
| Ratio corriente | 2.94 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.05 |
Rentabilidad
| Rentabilidad sobre capital | 31.61% |
| Rentabilidad sobre capital invertido | 23.33% |
| Rentabilidad sobre activos | 17.17% |
| Margen bruto | 69.20% |
| Margen operativo | 28.89% |
| Margen neto | 23.50% |
Empresas relacionadas: CDXS · CHRS · GNFT · IVVD · MDWD · NTHI · OABI
Explorar sector: Healthcare · Biotechnology
Más secciones de PLX: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones